We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Signet Announces Availability of Two Monoclonal Antibodies
Product News

Signet Announces Availability of Two Monoclonal Antibodies

Signet Announces Availability of Two Monoclonal Antibodies
Product News

Signet Announces Availability of Two Monoclonal Antibodies


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Signet Announces Availability of Two Monoclonal Antibodies "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Signet Laboratories, Inc. has announced the availability of two monoclonal antibodies, EGFR, clone F4 and VEGF, clone VG-1.

EGFR, clone F4, has been implicated in the development and progression of a number of human solid tumors including lung, breast, prostate, colon, ovary, head, and neck.

VEGF, clone VG-1, is a secreted glycoprotein that is a potent and specific mitogen for vascular endothelial cells that stimulates angiogenesis during embryonic development and tumor formation.

Signet's EGFR and VEGF antibodies are designed to offer researchers a valuable tool for cancer research.

These antibodies complement Signet's current product portfolio which includes markers such as D2-40, Cyclin D1, Cyclin E, HE4, and Hepsin.

Advertisement